Type 2 diabetes in China: Partnerships in education and research to evaluate new antidiabetic treatments

British Journal of Clinical Pharmacology

Volumn 61, Issue 6, 2006, Pages 702-705

  Donnelly, Richard ^a   Wang, Binhui ^a   Qu, Xianqin ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

China; Communication; Diabetes mellitus; Research; Traditional Chinese medicine; Training

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; AVE 0010; CANNABINOID 1 RECEPTOR; CJC 1132; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; IRBESARTAN; LIRAGLUTIDE; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RIMONABANT; RUBOXISTAURIN; SAXAGLIPTIN; SITAGLIPTIN; TELMISARTAN; TESAGLITAZAR; UNCLASSIFIED DRUG; VILDAGLIPTIN;

CARDIOVASCULAR DISEASE; CHINA; CHINESE MEDICINE; CLINICAL FEATURE; DEPLETION THIRST SYNDROME; DRUG EFFECT; EVALUATION RESEARCH; GASTROINTESTINAL SYMPTOM; HEALTH PROMOTION; HUMAN; INTERNATIONAL COOPERATION; MEDICAL EDUCATION; MEDICAL RESEARCH; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SYMPTOMATOLOGY;

DIABETES MELLITUS, TYPE 2; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INTERINSTITUTIONAL RELATIONS; MEDICINE, CHINESE TRADITIONAL;

EID: 33646932101     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02675.x     Document Type: Review

References (12)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care 2004 27: 1047 53.
2. Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, He J, Inter-ASIA Collaborative Group. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005 365: 1398 405.
3. Pan XR, Yang WY, Li GW, Liu J. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Co-Operative Group. Diabetes Care 1997 20: 1664 9.
4. Li LL, Zhang YM, Du JY, Mao XM, Wu XH, Ran XJ, Wang SG, Bai L, Li ND, Sun XF. Analysis of metabolic features and food composition related to the pathogenesis of type 2 diabetes mellitus in population of Uigurs and Kazaka in Xinjiang. Chin J Endocrinol Metab 2005 21: 141 2.
5. Dong Y, Gao W, Nan H, Yu H, Li F, Duan W, Wang Y, Sun B, Qian R, Tuomilehto J, Qiao Q. Prevalence of type 2 diabetes in urban and rural Chinese populations in Qingdao. China Diabet Med 2005 22: 1427 33.
6. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H. The burden of mortality attributable to diabetes. Diabetes Care 2005 28: 2130 5.
7. Gu D, Gupta A, Muntner P, Hu S, Duan X, Chen J, Reynolds RF, Whelton PK, He J. Prevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study of Cardiovascular Disease in Asia (Inter-ASIA). Circulation 2005 112: 658 65.
8. Pan C. Diabetes care in China: meeting the challenge. World Hosp Health Serv 2005 41: 29 32.
9. Wang Q. The present situation of TCM treatment for diabetes and its research. J Tradit Chin Med 2003 23: 67 73.
10. Wu S, Han Y, Li J. Treatment of incipient diabetic nephropathy by clearing Hawai the stomach-heat, purging the Herat FIRE, strengthening the spleen and tonifying the kidney. J Tradit Chin Med 2000 20: 172 5.
11. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In MacroVascular Events): a randomised controlled trial. Lancet 2005 366: 1279 89.
12. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve and 52-week efficacy of the dipeptidyl peptidase-IV inhibitor LAF 237 (vildagliptin) in metformin-treated patients with type 2 diabetes. Diabetes Care 2004 27: 2874 80.